Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor

PHASE3UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Hemophilia AHemophilia B
Interventions
DRUG

Recombinant human activated coagulation factor VII for injection

Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.

Trial Locations (9)

300020

RECRUITING

Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin

330006

RECRUITING

Jiangxi Provincial People's Hospital, Nanchang

400010

RECRUITING

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

410008

RECRUITING

Xiangya Hospital Central South University, Changsha

463599

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

510515

RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

530021

RECRUITING

The First Affiliated Hospital of Guangxi Medical University, Nanning

730013

RECRUITING

The First Hospital of Lanzhou University, Lanzhou

063099

RECRUITING

Affiliated Hospital of North China University of Science and Technology, Tangshan

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY